AI governance in clinical operations is the set of decisions, roles and controls that determine which AI tools a sponsor uses, how they are evaluated and who is accountable for their outputs. Emerging biopharma companies need governance scaled to their size. That means a lightweight but real framework, not an enterprise bureaucracy and not nothing.
Most small sponsors I work with are already using AI, often without realizing it. Their CRO uses it. Their eTMF vendor uses it. Their staff use generative AI tools to draft documents. Governance begins by acknowledging that reality.
What should an AI governance framework include?
A practical framework for a small or mid-sized sponsor has five elements.
Inventory. List every AI-enabled tool touching your clinical programs, including those used by vendors. Note what each does and which studies it affects.
Risk tiering. Classify each tool by its potential impact on participant safety, data integrity and regulatory submissions. A tool that drafts meeting notes is low risk. One that triages adverse events or informs monitoring decisions is high risk.
Ownership. Assign a named owner for each higher-risk tool. That person is responsible for understanding its purpose, reviewing its performance and escalating concerns.
Evidence and validation. For higher-risk tools, require documented validation for the intended use. For vendor tools, obtain validation summaries and confirm change control.
Oversight and review. Define how outputs are reviewed, how often performance is checked and what triggers reassessment. Document it so you can show an inspector.
Don't forget acceptable use
Generative AI deserves its own policy. Staff should know which tools are approved, what information may never be entered into public tools (protocols, patient data, unpublished results) and how AI-drafted content must be reviewed before use. A one-page policy with clear examples is better than a long one nobody reads.
How governance connects to regulation
This structure aligns with the direction regulators are taking. ICH E6(R3) expects fit-for-purpose systems and proportionate oversight. FDA's January 2025 draft guidance frames AI credibility around context of use and model risk. The EU AI Act introduces risk-based obligations for certain systems. A sponsor with a working inventory, risk tiers and documented oversight is well positioned for all three.
Keep it proportionate
Governance should enable, not obstruct. The purpose is to adopt useful tools with confidence, not to create approval queues that push people toward unsanctioned workarounds. Review the framework twice a year and adjust as your pipeline and vendor base change.
For a company without a dedicated quality or IT governance team, this is exactly the kind of structure a fractional clinical operations leader can put in place quickly.
ABRA Clinical Consulting provides fractional executive leadership for emerging sponsors building clinical operations governance.
